Physician profile
Anton Matveev
NPI 1356879092
$836.83
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $111 · 2021: $194 · 2022: $277.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $365.81 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.41 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $122.41 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $57.26 | 2021 | |
| Hikma Pharmaceuticals USA | $28.68 | 2022 | |
| Depuy Synthes Sales INC. | $24.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.80 | 2022 | |
| Ibsa Pharma INC. | $14.51 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.39 | 2022 | |
| Redhill Biopharma INC. | $14.13 | 2021 | |
| Lilly USA, LLC | $13.93 | 2021 | |
| Abbvie INC. | $13.18 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Matveev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.